Group 1 - Company Gilead Sciences-B (01672.HK) has selected ASC37, a next-generation subcutaneous injection for monthly administration targeting GLP-1R, GIPR, and GCGR, as a clinical development candidate [1] - The company plans to submit an Investigational New Drug (IND) application for ASC37 for the treatment of obesity to the FDA in the second quarter of 2026 [1] - ASC37 is developed using Gilead's AI-assisted structure-based drug discovery and ultra-long-acting platform technologies, showing significantly higher agonistic activity compared to retatrutide [2] Group 2 - In vitro studies indicate that ASC37 exhibits approximately 5 times, 4 times, and 4 times stronger agonistic activity on GLP-1R, GIPR, and GCGR, respectively, compared to retatrutide [2] - ASC37 has a longer observed half-life, allowing for monthly subcutaneous administration with an injection volume not exceeding 1 milliliter, which also provides scalability advantages in manufacturing [2] - The proprietary depot formulation of ASC37 has an average observed half-life of about 17 days in non-human primates, which is 7 times longer than that of retatrutide in standard liquid formulation [2] Group 3 - The advantages of ASC37 in terms of agonistic activity and observed half-life suggest its potential as a new generation therapy for obesity [3] - The company is advancing ASC37 into clinical stages, with Phase I studies expected to commence in the second half of 2026, marking a significant step towards improving treatment options for the obese population [3]
歌礼制药-B(01672.HK)：选定新一代每月一次皮下注射GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37进行临床开发